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Summary
 
Disruption of the balance between proteases and protease inhibitors is often associated with
pathologic tissue destruction. To explore the therapeutic potential of secretory leukocyte pro-
tease inhibitor (SLPI) in erosive joint diseases, we cloned, sequenced, and expressed active rat
SLPI, which shares the protease-reactive site found in human SLPI. In a rat streptococcal cell
wall (SCW)-induced model of inflammatory erosive polyarthritis, endogenous SLPI was unex-
pectedly upregulated at both mRNA and protein levels in inflamed joint tissues. Systemic de-
livery of purified recombinant rat SLPI inhibited joint inflammation and cartilage and bone de-
 
struction. Inflammatory pathways as reflected by circulating tumor necrosis factor 
 
a
 
 and
nuclear factor 
 
k
 
B activation and cartilage resorption detected by circulating levels of type II
collagen collagenase-generated cleavage products were all diminished by SLPI treatment in
acute and chronic arthritis, indicating that the action of SLPI may extend beyond inhibition of
serine proteases.
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I
 
njury and infection elicit a complex series of reactions in
the host designed to isolate and/or eliminate the inciting
agent(s) as well as to minimize and repair tissue damage.
Precise regulation of these mechanisms is crucial for the
maintenance of tissue integrity, and malfunction may result
in detrimental tissue destruction characteristic of rheuma-
toid arthritis and other chronic inflammatory diseases (1, 2).
In degenerative and inflammatory arthritis, degradation of
the proteoglycans and collagen of articular cartilage is me-
diated by excess neutral serine proteases and metallopro-
teinases (3, 4). The serine proteases contribute to activation
of matrix metalloproteinases, which are typically released in
a latent form (3–7), and also to cleavage of fibronectin and
other matrix molecules (8, 9). One of the most prominent
cell types in effusions of inflamed joints is the neutrophil,
the source of two serine proteases, elastase and cathepsin G.
Since neither neutrophil elastase nor cathepsin G requires
activation after release into the extracellular space, the ac-
tivities of these enzymes must be modulated by appropriate
inhibitors (10, 11). Serine protease inhibitors may thus play
an important role in controlling matrix turnover in inflam-
matory joint diseases.
 
The secretory leukocyte protease inhibitor (SLPI)
 
1
 
 is ac-
tive against a variety of serine proteases including neutro-
phil elastase and cathepsin G (12). Human SLPI (hSLPI) is
an 11.7-kD nonglycosylated protein originally identified
from epithelial cells at mucosal surfaces (13–16). It is com-
posed of two domains with the protease binding and inacti-
vating site in the COOH-terminal domain (17). Moreover,
recent evidence has revealed additional functions for this
serine protease inhibitor including both antibacterial and
antiretroviral activity, which may be associated with its
NH
 
2
 
-terminal domain (18–21). The production of SLPI by
murine macrophages and its association with the host re-
sponse to bacterial LPS suggested that SLPI might have an
expanded involvement in innate host defense and inflam-
matory responses (21–24). In humans, SLPI is primarily as-
sociated with epithelia and has not been identified in mac-
rophages (21).
To address these issues and define a role for SLPI in in-
 
1
 
Abbreviations used in this paper:
 
 AI, severity of arthritis; NF, nuclear factor;
PM, peritoneal macrophage; SCW, streptococcal cell wall; SLPI, secre-
tory leukocyte protease inhibitor. 
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flammatory joint diseases, we have cloned and sequenced
rat SLPI (rSLPI) cDNA and overexpressed and purified the
first biologically active recombinant rSLPI (rrSLPI) protein.
Using the well-characterized streptococcal cell wall (SCW)-
induced arthritis model (25), we initially monitored the en-
dogenous expression of rSLPI during the course of the ar-
thritis. Although it had not been observed previously,
rSLPI is clearly upregulated during both the neutrophil-
mediated acute phase and the T cell–dependent chronic
destructive phase of arthritis. Subsequently, we studied the
effects of administration of rrSLPI to the arthritic animals,
and found that the overt tissue destruction and inflamma-
tion typically seen in this model can be suppressed by sys-
temic injection of rrSLPI. Our results provide initial evi-
dence that modulation of the level of this endogenous
protease inhibitor may have therapeutic potential for treat-
ment of destructive inflammatory diseases.
 
Materials and Methods
 
Cloning and Sequencing of rSLPI cDNA.
 
RNA extracted from
peritoneal macrophages (PMs) was reverse-transcribed to
cDNA using an oligo-dT primer (Promega). Two pairs of
PCR primers were synthesized (22) to generate the complete
open reading frame. The first pair: upstream primer 5
 
9
 
-GGAG-
GCAAAAATGATGCTATC-3
 
9
 
, downstream primer 5
 
9
 
-CCGA-
GCACGAGTCCAGAGCCG-3
 
9
 
; and the second pair: upstream
primer 5
 
9
 
-CACCATGAAGTCCTGCGGCCT-3
 
9
 
, downstream
primer 5
 
9
 
-GGCGCCAATGTCAGGGATCAG-3
 
9
 
. cDNA am-
plifications were performed using a Perkin-Elmer PCR kit. 10 
 
m
 
l
of the PCR product using the first primer pair was reamplified
with the second primer pair. PCR products were resolved on an
agarose gel, transferred to a nitrocellulose membrane, and probed
with murine SLPI (mSLPI) cDNA. The cDNA fragment that hy-
bridized to mSLPI was subcloned and used to probe a rat mac-
rophage cDNA library in Lambda ZAP II (Stratagene). Inserts of
the positive clones were subcloned and sequenced with T3 and
T7 primers at the National Institute of Dental and Craniofacial
Research DNA core facility.
 
Sequence and Database Analysis.
 
The EMBL, Swissprot, and
GenBank molecular biology databases were searched using the
network service (National Center for Biotechnology Informa-
tion, NLM, Bethesda, MD) and the FASTA program from the
Genetics Computer Group (GCG) Wisconsin Sequence Analysis
Software Package (University of Wisconsin). Multiple sequence
alignments were performed using ClustalW alignment in Mac-
Vector software (Oxford Molecular Group, Oxford, UK).
 
RNA Isolation and Northern Blot Analysis.
 
PBMCs and poly-
morphonuclear neutrophils (PMNs) were isolated from female
Lewis rats as previously described (25). Resident PMs were col-
lected by PBS lavage of the peritoneal cavity. Total RNA was
isolated by the RNeasy protocol (Qiagen). 8 
 
m
 
g of total RNA
was then subjected to Northern blot analysis using [
 
32
 
P]dCTP-labeled
rSLPI and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA as the probes.
 
Expression of rSLPI cDNA and Purification of rSLPI Protein.
 
The rSLPI cDNA encoding the mature secreted protein was
generated by PCR with an upstream primer 5
 
9
 
-GGCAAAAAT-
GATGCTATC-3
 
9
 
 and a downstream primer 5
 
9
 
-TTACACT-
GGGGGAAGGCAGA-3
 
9
 
 with BamHI and SalI adaptors, re-
spectively. The BamHI–SalI cDNA fragment was subcloned into
 
a prokaryotic expression vector pQE30 (Qiagen Inc.) with an in-
frame ATG and the hexahistidine tag to the NH
 
2
 
-terminus. Bidi-
rectional sequencing verified the correct sequence and reading
frame. 
 
Escherichia coli
 
 strain M15 was transformed with the rSLPI
expression construct and grown in a 10-liter fermentation system
at 37
 
8
 
C with ampicillin (100 
 
m
 
g/ml) and kanamycin (25 
 
m
 
g/ml)
until an OD of 10 was reached. rSLPI expression was induced by
addition of 1 mM IPTG for 5 h at 37
 
8
 
C. The cells were then har-
vested and the pellet was resuspended in 50 mM Na-phosphate
buffer (pH 8.0) containing 300 mM NaCl, and in 10 mM imida-
zole. After sonication and RNase A and DNase I treatment, se-
quential 15,000 and 50,000 
 
g
 
 centrifugations were performed.
The supernate was mixed with pre-equilibrated Ni-NTA resin
and incubated at 4
 
8
 
C for 1 h before being packed into a chro-
matographic column. Step-elution with 50, 75, 100, 125, and
150 mM imidazole was then carried out. The eluate from 75 mM
imidazole, which showed anti-elastase, anti-cathepsin G, and
anti-chymotrypsin activities, was dialyzed against sodium phos-
phate buffer (PBS, 10 mM sodium phosphate, 0.9% saline, pH
7.4), concentrated, filter-sterilized, and stored in aliquots at
 
2
 
80
 
8
 
C. 25 mg of purified rrSLPI protein was isolated from 50 g
of wet weight of 
 
E. coli
 
, which constituted 0.6% of the total solu-
ble protein. rrSLPI was sequenced by Edman degradation
(CBER, FDA, Bethesda, MD) to confirm identity. The molecu-
lar weights of the purified proteins were determined by mass
spectrometry (Dr. Lewis Pannel, NIDDK, NIH, Bethesda, MD).
An 8.4-kD truncated HIS-rSLPI recombinant protein (the
COOH-terminus ends at Arg
 
64
 
 of the mature rSLPI protein)
was obtained using the same purification scheme, which has no
protease reactive site and lacked anti-elastase, anti-cathepsin G,
and anti-chymotrypsin activities. Endotoxin levels of both the
full-length and truncated rrSLPI protein preparations were
found to be 
 
#
 
25 pg/ml (detection limit).
 
Western Blot Analysis.
 
Rabbit polyclonal antibodies gener-
ated against the rSLPI peptide EGGKNDAIKIGAC (Quality
Controlled Biochemicals, Inc.) were affinity purified and used
for immunoblotting, ELISA, and immunohistochemical studies.
 
Protease Inhibition Assays.
 
Elastase activity was measured as
the amidolytic effect of human neutrophil elastase (15 nM; Cal-
biochem) on pyroGlu-Pro-Val-pNA (0.5 mM; Chromogenix)
after 10 min at 37
 
8
 
C (26). Trypsin activity was determined by
measuring the amidolytic effect of 
 
l
 
-1-Tosylamide-2-phenyl-
ethyl chloromethyl ketone (TPCK)-treated bovine pancreatic
trypsin (Sigma Chemical Co.) on the chromogenic substrate
 
N
 
-
 
a
 
-benzoyl-
 
l
 
-Arg-pNA (Boehringer Mannheim, Inc.) (27).
Chymotrypsin (12.5 nM) and cathepsin G (32 nM) (Calbio-
chem) activities were measured using the chromogenic sub-
strate 
 
N
 
-suc-Ala-Ala-Pro-Phe-pNA (Sigma Chemical Co.) at
0.1 and 0.4 mM concentrations for 15 and 20 min, respectively
(28, 29). In all assays, the respective enzymes were incubated
with or without different concentrations of purified rrSLPI at
37
 
8
 
C for 20 min. Then the substrate for each enzyme was
added and the residual activity was measured as the change in
absorbence at 405 nm after an appropriate incubation time at
37
 
8
 
C.
 
Induction and Monitoring of Arthritis.
 
Arthritis was initiated in
female Lewis rats (Charles River Breeding Labs., Inc.) by an in-
traperitoneal injection of group A SCW (Lee Labs.) (25). The
severity of arthritis (AI) was determined by blind scoring of
each ankle and wrist joint, based on the degree of swelling,
erythema, and disfigurement on a scale of 0–4 and adding the
scores for all four limbs during the course of the study (26–28 d).
Rats were randomly assigned to five groups for two separate 
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experiments (I and II) as follows: control animals, which re-
ceived PBS on day 0 (
 
n
 
 5 
 
6 for both experiments); SCW-
injected animals (
 
n
 
 5 
 
6 for both experiments); SCW-injected an-
imals treated with rrSLPI on days 1 and 9 (
 
n
 
 5 
 
6 for each
dosage group in experiment I, and 
 
n
 
 5 
 
12 for experiment II);
SCW-injected animals treated with rrSLPI on day 13 (
 
n
 
 5 
 
3 for
each dosage group for experiment I, and 
 
n
 
 5 
 
12 for experiment
II); and SCW-injected animals treated with truncated rrSLPI on
days 1 and 9 (
 
n
 
 5 
 
3 for each dosage group for experiment I, and
 
n
 
 5 
 
9 for experiment II). In experiment I, 100 
 
m
 
g or 1 or 5 mg
of purified full-length or truncated rrSLPI was injected intra-
peritoneally at the times specified for each group of animals; in
experiment II, 100 
 
m
 
g of full-length or truncated rrSLPI was
used. Statistical significance was ascertained using the analysis of
variance followed by Scheffe’s post-hoc test. Radiographs were
taken as previously described (25). Excised ankle joints were pro-
cessed for histopathology (25), and sections were stained with anti-
rSLPI antibody (5 
 
m
 
g/ml) using Vectastain-ABC kit with DAB
substrate (Vector Labs.) and counterstained with methyl green (25).
 
ELISA Assays.
 
Rat plasma samples (1:2) were diluted in the
appropriate dilution reagent and the levels of TNF-
 
a
 
 were mea-
sured by ELISA (Biosource International). The plasma levels of
rrSLPI were measured by our ELISA assay. In brief, Immulon 4
HBX microtiter plates (DYNEX Technologies, Inc.) were
coated with 200 
 
m
 
l of anti-tetra-HIS antibody (3 
 
m
 
g/ml;
Qiagen), washed four times in PBS, and incubated in blocking
buffer (2% sucrose, 0.1% BSA, and 0.9% sodium chloride) for 2 h.
Standard ELISA procedure was then performed using rabbit
anti-rSLPI (5 
 
m
 
g/ml) as the primary antibody, alkaline phos-
phatase–conjugated anti–rabbit antibody as secondary antibody
(1:4,000; Boehringer Mannheim Biochemicals), and 
 
p
 
-nitro-
phenyl phosphate as substrate (Sigma Chemical Co.).
 
Electromobility Shift Assay.
 
Joint samples were obtained at the
indicated times and processed in a freezer/mill (SPEX Cer-
tiPrep) in the presence of liquid nitrogen (25). Nuclear proteins
were isolated from the powdered joint tissue by homogeniza-
tion in lysis buffer (20 mM Tris, pH 7.6, 120 mM NaCl, 1%
NP-40, 10% glycerol, 10 mM NaPPi, 100 mM NaF, 2 mM
Na-orthovanadate, 1 mM AEBSF, and 5 
 
m
 
g/ml leupeptin).
Electromobility shift assay (EMSA) for nuclear factor (NF)-
 
k
 
B
was performed using a radiolabeled NF-
 
k
 
B consensus oligonu-
cleotide probe (Promega) as previously described (30).
 
Collagen Cleavage ELISA.
 
Rat plasma samples were col-
lected by tail bleeding or intracardiac puncture. Plasma levels of
type II collagen cleavage product Col2-3/4C long neoepitope
were monitored by a solution phase ELISA assay based on a
published method (31). The Col2-3/4C long neoepitope re-
sides at the COOH terminus of the TC
 
A
 
 piece produced by
cleavage of the 
 
a
 
1(II) chain by collagenase. The mouse mAb
used in the assay is distinct from the rabbit antibody described
previously (31) in that it recognizes only the cleaved 
 
a
 
1(II) chain
and thus is absolutely specific for type II collagen (Billinghurst,
R.C., M. Ionescu, M.-A. Fitzcharles, E. Keystone, and A.R.
Poole, manuscript in preparation).
 
Results
 
Cloning and Sequencing of rSLPI cDNA.
 
rSLPI mRNA
was identified by reverse transcriptase PCR using nested
primers designed against the mSLPI open reading frame
(22). A 400-bp cDNA fragment was isolated and used to
probe a cDNA library from rat PMs. A 490-bp cDNA
fragment was isolated, sequenced, and found to contain an
open reading frame (bp 9–402, Fig. 1 A) encoding a pre-
dicted translation product of 131 amino acids with an esti-
mated molecular mass of 14 kD. The putative rSLPI coding
sequence shares 88% homology with murine SLPI (mSLPI)
and 75% with hSLPI. At the amino acid level, rSLPI exhib-
its 83 and 58% identity to mSLPI and hSLPI, respectively
(Fig. 1 B). 16 cysteine residues are conserved in the mature
SLPI (residues 26–131, Fig. 1 B) and the serine protease
binding site in hSLPI (Leu
 
72
 
 of the mature protein) is iden-
tical in rSLPI (Fig. 1 B). However, by Northern blot analy-
sis, distinct tissue distribution patterns compared with hu-
mans were observed (Song, X.y., L. Zeng, W. Jin, and
S.M. Wahl, manuscript in preparation). Moreover, although
no detectable hSLPI mRNA has yet been observed in human
mononuclear cells and macrophages, rSLPI was constitu-
tively present at very high levels in naive PMs, less abundant
in PBMCs, and essentially absent in resting PMNs (Fig. 2 A).
 
Modulation of rSLPI Expression in SCW-induced Arthritic
Joints.
 
When rSLPI mRNA was monitored during the
Figure 1. cDNA sequence of rSLPI and amino acid sequence compar-
ison among human, murine, and rat SLPI. (A) Nucleotide sequence of
rSLPI is shown in plainface, and the amino acid sequence of the mature
protein in boldface below the nucleotide sequence. The amino acid se-
quence for the signal peptide is underlined. Asterisk, stop codon. (B)
Comparison of amino acid sequences of human, murine, and rat SLPI us-
ing ClustalW alignment. Conserved residues are shaded in dark color, and
conserved cysteine residues are indicated by asterisks. The active site for
protease binding is underlined with the two key residues double under-
lined. 
538
 
Recombinant rSLPI Inhibits SCW-induced Joint Destruction
 
course of synovial inflammation and compared with the
low constitutive SLPI mRNA levels in control joints, a
striking biphasic expression pattern was observed during
the course of the disease. The increase in rSLPI mRNA
coincided with the peak acute (day 4 after SCW injection)
and chronic (day 30) inflammatory responses (Fig. 2 B), but
decreased significantly at the onset of the remission phase
(day 7), and was negligible at the onset of chronic disease
(day 14). These findings suggest that failure to produce suf-
ficient SLPI or to maintain the initial elevated levels of the
protease inhibitor preceding chronic disease may facilitate
joint destruction.
Assessment of the origins of SLPI in the inflamed syn-
ovium revealed that rSLPI protein was found in infiltrating
inflammatory cells consistent with SCW-induced mRNA
expression (Fig. 2 A), and was also associated with some
chondrocytes and cells in the bone marrow (Fig. 2, D and E).
 
Recombinant rSLPI Inhibits SCW-induced Joint Inflamma-
tion.
 
Because SLPI levels were minimal during the inter-
val before joint destruction becomes most pronounced, we
attempted to restore levels of the protease inhibitor by exo-
genous delivery of active rrSLPI. For this purpose, a mature
rSLPI–HIS fusion protein was expressed, purified to ho-
mogeneity (Fig. 3, A–C), and found to contain a polypep-
tide recognized by both anti-rSLPI (Fig. 3 C, lane 4) and
 
anti-HIS tag antibodies (data not shown). This full-length
fusion protein (molecular mass 
 
z
 
12 kD; Fig. 3 C, lane 4)
exhibited antiprotease activity toward human neutrophil
elastase (Fig. 3 D), cathepsin G, and bovine chymotrypsin,
but not trypsin (data not shown), and was used in the sub-
sequent in vivo study. A COOH-terminally truncated
form of the rrSLPI protein without anti-elastase, anti-
cathepsin G, or anti-chymotrypsin activities was used as the
control agent in the following animal experiments.
Based on the SLPI expression profile (Fig. 2, B–F), full-
length or truncated rrSLPI (0.1, 1, and 5 mg) was adminis-
tered intraperitoneally before the clinically evident acute
response to SCW or preceding the chronic inflammatory
response, when endogenous SLPI was at a low ebb. As
early as 2 d after the first full-length SLPI-injection (0.1 mg),
Figure 2. SLPI expression in SCW-induced arthritis. (A) RNAs from
PMNs, PBMCs, and PMs of control and SCW arthritic (day 26) animals
were probed with rSLPI and rat GAPDH cDNA probes. (B) Total RNA
from ankle tissues at indicated times after SCW injection were blotted to
a Nytran membrane and probed with rSLPI cDNA. The ethidium bro-
mide–stained gel demonstrates the amount of 28S and 18S RNAs. Data
are representative of three experiments. (C–F) Immunohistochemical de-
tection of rSLPI protein (brown stain) in joint sections before (C), 4 d af-
ter (D), and 26 d after SCW injection (E, F). Rabbit IgG was used as con-
trol in F. Syn, synovium; JS, joint space; C, cartilage; BM, bone marrow.
Figure 3. Expression and purification of active rrSLPI. (A) Diagram of
HIS–rSLPI fusion protein for step-elution from Ni-NTA column. (B)
SDS-PAGE of purified proteins: 1, sonicated induced cells; 2, lysate from
15,000 g centrifugation; 3, dialyzed lysate from the sequential 50,000 g
centrifugation; 4, 75 mM imidazole elute fractions; MW, markers. (C)
Immunoblot of B using anti-rSLPI peptide antibody as described in Ma-
terials and Methods. (D) rrSLPI (lane 4) possesses antiprotease activity to-
ward human neutrophil elastase (shown), cathepsin G, and chymotrypsin.
Different concentrations of SLPI were shown on the x-axis, and the frac-
tional elastase activity at each inhibitor concentration compared with un-
inhibited activity was shown on the y-axis. 
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a reduction in AI was evident that was more significant by
day 4 of the acute response (AI
 
 5 
 
3.17 
 
6
 
 0.86, 
 
n
 
 
 
5 
 
12; vs.
5.88 
 
6
 
 0.98 in SCW animals, 
 
n
 
 
 
5 
 
12, 
 
P
 
 
 
5 0.035, Fig. 4
A). The effects of 0.1, 1, and 5 mg of rrSLPI were similar
based on AI (data not shown). However, the impact of a
single injection of only 0.1 mg of full-length rrSLPI was
transient, as the clinical and histopathological symptoms re-
appeared during the late chronic disease stage, albeit at re-
duced levels (data not shown). Importantly, joint swelling,
erythema, and disfigurement, the hallmarks of chronic ar-
thritis, a response typically considered T cell– and mac-
rophage- rather than neutrophil-dependent, were drasti-
cally curtailed after a second rrSLPI injection 9 d after
SCW (AI 5 2.83 6 1.17 vs. 9.58 6 1.19, n 5 12, day 26,
P 5 0.0065, Fig. 4 A) and remained suppressed for the du-
ration of the experiment. Radiographic analysis revealed
that compared with SCW-injected animals, which exhibit
overt erosion of cartilage and bone (Fig. 4 B), full-length
rrSLPI-treated animals had minimal pathological changes
with only mild soft tissue swelling (Fig. 4 C). In contrast,
treatment of SCW-injected animals with the antiproteolyt-
ically inactive truncated rrSLPI caused no significant
changes in disease severity (Fig. 4 D). Moreover, a single
injection of full-length rrSLPI at the beginning of chronic
arthritis (day 13) appeared to reduce the disease severity,
achieving statistical significance within 10 d (Fig. 4 A).
When plasma levels of rrSLPI were examined in rrSLPI-
treated (1 mg) and untreated SCW animals, 2,652 pg/ml of
rrSLPI was detected in rrSLPI-treated animals 2 h after in-
jection, which declined over the next 16 h. SLPI levels
were not detected in control or untreated arthritic animals.
Finally, no apparent adverse effects were observed in
rrSLPI-treated (1 mg) animals, which maintained their
body weight at a level similar to the nonarthritic control
animals (body wt 5 175.7 6 1.8 g in rrSLPI-treated ar-
thritic animals vs. 158.6 6 1.76 g in untreated SCW ar-
thritic animals and 184.5 6 2.4 in nonarthritic control ani-
mals, day 26).
Impact of rrSLPI on Extracellular Matrix Destruction. Cir-
culating type II collagen collagenase–generated cleavage
products reflect the increase in cleavage in degenerate artic-
ular cartilage in human osteoarthritis (31), but have not
been analyzed in experimental animal models. A new assay
to detect a hidden type II collagen epitope in the COOH-
terminal three-quarter–length fragment (Col2-3/4C long
neoepitope), which is exposed only when native triple he-
Figure 4. Suppression of arthritis by
rrSLPI. (A) Arthritis was initiated by a single
intraperitoneal injection of SCW on day 0
and the articular index (AI) measured as de-
scribed in Materials and Methods for the
course of the study (s). An intraperitoneal
injection of 0.1 mg of the purified active
rrSLPI protein was administered 24 h and
again on day 9 after SCW (d) or only on
day 13 (h). Each point represents the mean
AI 6 SEM for each group of animals (n 5
12) and significant decreases in AI with
treatment are indicated as *P , 0.05 and
**P , 0.01. (B and C) Radiographs of rep-
resentative animals 26 d after SCW injec-
tion (B) and rrSLPI-treatment on days 1 and
9 (0.1 mg) (C). (D) The effect of truncated
rrSLPI (0.1 mg, hatched bars) administered
on days 1 and 9 after SCW on acute and
chronic arthritis was compared with that of
the full-length rrSLPI (solid bars). The artic-
ular index of untreated SCW-injected ani-
mals was shown as open bars. Each point
represents the mean AI 6 SEM for each
group of animals (n 5 12) and significant
differences are indicated by *P , 0.05 and
**P , 0.01. (E) rrSLPI suppresses the in-
creased cleavage of type II collagen. Plasma
samples were collected during the acute
(day 4), remission (day 10), and chronic
phases (day 26) of arthritis and Col2-3/4C
long neoepitope quantified by ELISA. Data
shown are the means 6 SEM for each
group of animals (n 5 6). SCW1rrSLPI
represents the group of animals that have
been injected with active rrSLPI on day 1
and 9 after SCW (solid bars) and PBS repre-
sents the control animals injected with
phosphate buffered saline (open bars). *P ,
0.05, **P , 0.001.540 Recombinant rSLPI Inhibits SCW-induced Joint Destruction
lical type II collagen is cleaved by collagenase, enabled us to
quantify cartilage degradation in SCW arthritic rats. We
demonstrate that Col2-3/4C long neoepitope increased in
plasma with disease progression (Fig. 4 E), paralleling the
evolution of cartilage destruction observed in these animals
(Fig. 4 B) (25). Interestingly, during the remission phase,
when inflammation and swelling typically decline, collagen
cleavage appears to persist with the spill-over of cleavage
products into the circulation. After a single full-length
rrSLPI treatment on day 1 after an arthritogenic injection
of SCW, a significant reduction (two- to threefold) in
Col2-3/4C long neoepitope plasma levels was detected
even during acute arthritis (Fig. 4 E). The lack of signifi-
cant decrease in cleavage products in rrSLPI-treated ar-
thritic animals during remission (day 10) is consistent with
the clinical and pathological data in which a single treat-
ment with full-length rrSLPI does not fully sustain suppres-
sion of the arthritis through the chronic phase. Although a
second rrSLPI injection was administered on day 9, this
probably represents an inadequate interval of time to effect
a further reduction in enzymatic profile on day 10. How-
ever, the injection of SLPI on day 9 did have a profound
impact on the subsequent evolution of cartilage and matrix
destruction associated with chronicity. In fact, full-length
rrSLPI appeared to nearly eliminate the joint destruction as
quantified by multiple parameters, including AI, radiologic
assessment of joint destruction, and the release of type II
collagen cleavage products (Fig. 4).
Suppression of Inflammatory Mediators by rrSLPI. In addi-
tion to proteolytic blockade of matrix degradation, histo-
pathological analysis revealed reduced evidence of synovial
inflammation in rrSLPI-treated arthritic animals. It has
been shown that TNF-a can induce SLPI production in
epithelial cells (32), and SLPI can in turn inhibit TNF-a
production in macrophages (21, 22). To determine
whether exogenously administered active rrSLPI could re-
inforce the endogenously produced SLPI to antagonize
SCW-induced TNF-a (25), we compared plasma levels of
TNF-a in full-length rrSLPI-treated and untreated arthritic
animals over the course of the disease. Plasma levels of
TNF-a in arthritic animals were elevated during the acute
phase, decreased in remission, and markedly increased in
the chronic phases of the disease (reference 33; Fig. 5 A).
However, after administration of full-length rrSLPI on days
1 and 9, there was a rapid and sustained decrease in detect-
able levels of circulating TNF-a (Fig. 5 A). Since SCW
(30) and TNF-a both activate NF-kB, which is responsible
for the transcription of multiple inflammatory mediators in-
cluding TNF-a (34), the consequences of rrSLPI injection
on NF-kB activity in active rrSLPI-treated and untreated
animals during both acute (Fig. 5 B) and chronic (data not
shown) arthritis were examined. By EMSA, NF-kB was
strongly activated in SCW-induced arthritic joint tissue as
compared with PBS-injected control animals, and this acti-
vation was suppressed by rrSLPI (Fig. 5 B). These data im-
plicate a potential role for rrSLPI in breaking the positive
feedback loop between TNF-a and NF-kB activation,
thereby dampening SCW-induced joint inflammation.
Discussion
SLPI, a serine protease inhibitor with potent neutralizing
activity for leukocyte enzymes such as neutrophil elastase, is
upregulated in response to bacteria and bacterial products
(21, 22, 24). Here we demonstrate that, in contrast to
hSLPI, rSLPI, like its murine counterpart (24), is expressed
in monocytes and PMs and, apparently, other cells exposed
to bacterial cell wall components. Our identification of
SLPI in articular chondrocytes is consistent with recent re-
ports, although it is still controversial whether SLPI is pro-
duced by these cells in situ or is sequestered into the carti-
lage matrix (35–37). Moreover, we have expressed biologically
active recombinant rSLPI, and show that when delivered
to animals in which bacterial products induce arthritic le-
sions, SLPI can profoundly inhibit proteolytic tissue de-
struction and joint inflammation. This effect of rrSLPI on
SCW-induced arthritis and the parameters monitored im-
plies that SLPI inhibits multiple pathways either directly as
a consequence of its antiprotease activity or via yet to be
determined regulatory pathways.
SCW-induced arthritis presents a biphasic disease process
with a neutrophil-dependent acute phase and a prolonged
T cell–dependent, macrophage-mediated chronic phase
that manifests z2 wk after SCW injection (25). Although
the acute phase is considered reversible, the chronic de-
structive disease presents irreversible changes with progres-
sive pannus invasion of the cartilage and bone, and eventual
loss of normal joint structure and function. The increasing
differences between nonarthritic and SCW arthritic animals
in type II collagen cleavage as disease progresses is, in part,
due to a gradual decrease in normal type II collagen cleav-
age in young control animals as they age, associated with
the closure of the growth plate (38). Parallel to the biphasic
disease manifestation, the expression of endogenous SLPI is
substantially upregulated at both mRNA and protein levels.
The unexpected increases in endogenous SLPI observed
during both acute and chronic arthritis most likely repre-
sent an attempted defense against the elevated serine pro-
Figure 5. (A) rrSLPI inhibits TNF-a production. Plasma samples of
SCW-injected (hatched bar) and SCW animals that have received 0.1 mg
of active rrSLPI on days 1 and 9 (solid bar) were collected as indicated
and analyzed by ELISA. Each point represents the mean 6 SEM (n 5 6).
**P , 0.01. (B) rrSLPI suppresses NF-kB activity in SCW animals. Pro-
teins were extracted from joint samples of PBS-injected nonarthritic and
SCW-injected and active rrSLPI-treated SCW arthritic animals 3 d after
SCW or PBS and 2 d after rrSLPI injection and subjected to EMSA.541 Song et al.
teases triggered by SCW activation. However, expression
of SLPI nearly vanishes in the interval preceding chronic
destructive disease, suggesting that this loss of SLPI activity
may contribute to the joint destruction typical of chronic
arthritis. In this regard, the therapeutic effect of exoge-
nously delivered rrSLPI might result from direct inhibition
of the serine protease cascade, initiated not only by neutro-
phil elastase, but also by that derived from both lympho-
cytes and macrophages (39–41). Consistent with this hy-
pothesis, denaturation of type II collagen in articular
cartilage as reflected by quantifiable circulating levels of a
neoepitope resulting from cleavage of collagen by collage-
nase, the Col2-3/4C long neoepitope, was significantly
suppressed by exogenously delivered rrSLPI during both
the acute and chronic phases of the disease. The persistent
collagen cleavage during remission, when inflammatory ac-
tivity is low, indicates that the devastating cartilage destruc-
tion associated with chronicity is the consequence of smol-
dering proteolysis. Consequently, the therapeutic effect of
exogenous SLPI on chronic arthritis may also involve sup-
pression of protease activities existing at the transition be-
tween acute and chronic arthritis.
By providing exogenous active rrSLPI, the severity of
disease at the clinical, histological, and molecular levels can
be reduced. By neutralizing elastase, which cleaves not only
elastin, but also collagen, fibronectin, and proteoglycans
leading to cartilage and matrix degradation, this protease
inhibitor may have multiple beneficial actions (8, 9). More-
over, because elastase (3, 5) and the plasminogen–plasmin
system (3) can activate latent matrix metalloproteinases,
SLPI may also indirectly block matrix metalloproteinase–
mediated matrix cleavage. Recent evidence indicates that
SLPI inhibits synthesis of macrophage collagenase and im-
pairs PGE synthesis (42), implicating SLPI in the interrup-
tion of a proteolytic cascade of inflammatory events that
evolve to tissue destruction (43, 44).
In addition to inhibiting proteolytic tissue destruction,
SLPI appears to have multiple antiinflammatory actions.
SLPI inhibits TNF-a production, probably through its
ability to block NF-kB activation (22, 45). Our demonstra-
tion of SLPI’s effect on TNF-a production and NF-kB ac-
tivity in vivo complements the in vitro findings that SLPI is
upregulated by proinflammatory stimuli including LPS,
TNF-a, IL-6, and IL-1b, and subsequently inhibits TNF-a
and nitric oxide production. These pathways may underlie
SLPI’s antiinflammatory functions in vivo (22, 24, 32).
Based on the similarities between human rheumatoid ar-
thritis and SCW-induced experimental arthritis, and the
shared protease reactive site in hSLPI and rSLPI, our study
provides initial preclinical evidence in support of the use of
this serine protease inhibitor in alleviating arthritic pathol-
ogy. SLPI may represent a prototype therapeutic approach
for multiple inflammatory destructive diseases.
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